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Abstract
Malignant mesothelioma (MM) is a highly aggressive tumor with a dismal prognosis. The
incidence of MM is increasing as a result of widespread exposure to asbestos. As for the molecular
alterations that occur in MM, chromosome alterations including homo-deletion of the P16 and P14
genes located in the 9p21 are well known. Mutations are rare in the P53 and Ras genes, which
are frequently present in epithelial solid tumors. However, mutations are frequently present in
the neurofi bromatosis type 2 gene. Epigenetic alterations including DNA methylation have been
found in the MM, the profi le of which is diff erent from that of lung cancer, although differential
diagnosis is sometimes clinically difficult. As in other malignant tumors, genes that are related to
immortalization, proliferation, metastasis, angiogenesis, and anti-apoptosis are also overexpressed
in MM, contributing to its malignant phenotype. It is of interest that simian virus 40 has been
implicated to be one of the causative factors of MM in western countries. Although the causative
role of asbestos is well-known in MM, much less information is available for MM than for other
malignant tumors regarding the molecular alterations that occur in the disease. In terms of future
tasks, it will be necessary to apply the knowledge that is learned about molecular alterations to
clinical practice and to further elucidate the pathogenesis of MM with extensive research.
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alignant mesothelioma (MM) is an aggressive 
tumor that develops from the pleura or other 
mesothelial surfaces and is strongly associated with 
exposure to asbestos.  Many MMs have already pro-
gressed by the time they are discovered and show an 
extremely poor prognosis [1].  Multimodality therapy 
centered on surgical resection is indicated for the 
treatment of MM in the early stage,  but so many cases 
are found at advanced stage.  No method of treatment,  
including chemotherapy or radiotherapy,  has yet been 
established for advanced cases.  Thus,  new strategies 
for the diagnosis and treatment of MM are needed.  In 
fact,  much less information regarding molecular bio-
logical alterations is available for MM than for other 
solid neoplasms,  even though an understanding of their 
molecular biological characteristics is needed to 
establish diagnostic,  treatment,  and prevention meth-
ods.  This review summarizes the representative 
molecular biological alterations in MM that have been 
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demonstrated thus far.
Molecular Alterations in MM
　 Eﬀ ect of asbestos. Asbestos,  especially 
amphiboles ﬁ bers with a high length-to-diameter ratio,  
is a well-established carcinogen of MM [2,  3].  
Research on the molecular alterations produced by 
asbestos in mesothelial cells has been under way since 
the 1990s.  There may be a 35- to 40-year latent 
period before the development of asbestos-induced 
MM.  The clinical manifestations of MM are thought 
to arise as a result of a build-up of many molecular 
alterations.  Asbestos ﬁ bers show increased expres-
sion of the proto-oncogenes c-fos and c-jun [4]. These 
proteins are localized in the nucleus,  resulting in cell 
proliferation and transcription,  which are thought to 
be the initial intranuclear alterations caused by asbes-
tos.  Asbestos in nature also has a cytotoxic eﬀ ect on 
mesothelial cells in vitro.  On the other hand,  asbestos 
also promotes secretion of the pro-inﬂ ammatory cyto-
kine TNF-ｸ in mesothelial cells and macrophages,  
leading to the activation of NF-κB through promoting 
the expression of the TNF-ｸ receptor in mesothelial 
cells [5,  6].  Because NF-κB plays a role in cell pro-
liferation and anti-apoptosis,  MM cells are assumed to 
undergo neoplastic transformation as a result of the 
activation of the NF-κB pathway [5].
　 Chromosome alterations. Numerous altera-
tions at the chromosome level have been reported in 
MM based on the results of comparative genomic 
hybridization and loss of homozygosity (LOH) analy-
ses.  While both chromosome ampliﬁ cations and dele-
tions have been found,  deletions are more frequent 
than ampliﬁ cations,  with more involved sites.  There 
have been many publications regarding the alterations 
of chromosome loci.  The most frequent deletions and 
the chromosome locus ampliﬁ cations that have been 
published are shown in Table 1 [7ﾝ17].  A particu-
larly high frequency of homo-deletions is seen in the 
9p21 region in MM,  thus causing a high frequency of 
deletions of the P16 and P14 genes that are located on 
9p21 and a loss of expression of their proteins [18].  
Indeed,  an attempt is being made to apply this ﬁ nding 
for diagnosis by using the ﬂ uorescence in situ hybrid-
ization method to identify homo-deletion of the P16 
gene in MM cells in pleural ﬂ uid [19].  As a potential 
therapeutic strategy,  cell cycle arrest is induced in 
MM cells to which either p16 or p14 expression con-
structs have been introduced [20,  21].  The mecha-
nism of the P16 alterations and malignant transforma-
tion has been found to involve the loss of p16 protein,  
which causes a breakdown of the cell-cycle control 
mechanism by inhibiting the phosphorylation of retino-
blastoma (Rb) protein,  which controls the cell cycle.  
In addition,  the loss of p14 protein results in the acti-
vation of mdm2 protein,  a p53 ubiquitin ligase,  and 
this activation is thought to be linked to the destabili-
zation of p53 protein,  thus causing alterations in cell 
cycle control [22] (Fig. 1).  Deletion of P16 is sig-
niﬁ cantly more common in MMs that have a sarcoma-
tous component and is considered to be a negative 
prognostic factor for MM independent of the sarcoma-
toid type [23].
　 Diﬀ erences in chromosome alterations have also 
been reported in the histological subtypes,  which may 
contribute to the biological and morphological diﬀ er-
ences among subtypes [13,  24].
　 Gene mutations. Neuroﬁ bromatosis type 2 
(NF2) gene mutations have been discovered in MM 
[25].  The NF2 gene is originally known to be the 
causative gene in neuroﬁ broma (type II).  NF2 gene 
mutations have been observed in approximately 50ｵ 
of MM cases.  There has been a report of LOH of 
22q12,  where the NF2 gene is located,  in almost 
100ｵ of mutant cases [26].  Because NF2 gene muta-
tions are not observed in lung cancer,  the presence of 
these mutations is considered useful for making the 
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diﬀ erential diagnosis from lung cancer,  especially 
from adenocarcinoma of the lung [25,  27,  28].  
However,  since there are no hot spots at the mutation 
sites in the NF2 gene,  it is necessary to examine all 
17 exons in order to detect mutations,  as it is not 
realistic to use NF2 gene mutations as a marker for 
diagnosis at the present time.  When a simple method 
to detect NF2 gene mutations is developed,  the NF2 
gene is likely to become a valuable diagnostic marker.  
While mutations in the Wilms’ tumor 1 (WT1) gene 
have also been found,  their frequency is low,  and thus 
it is diﬃ  cult to use them for molecular diagnosis [29,  
30].  Mutations in other genes including the P53,  Ras,  
and RB genes,  which have been found at high frequen-
cies in other malignant tumors,  are very rare [31ﾝ
33].  It is assumed that alterations in the P53 and RB 
genes in particular are unnecessary,  because even if 
the P53 and RB genes are of the wild type,  they do not 
function properly because of the P14 and P16 genes 
deletions as described above.  However,  the reason 
that the DNA sequences of P53 and RB are intact in 
MM is unclear.  This may be a crucial key to under-
standing the pathogenesis of MM.
　 DNA methylation. Gene inactivation by epi-
genetic alteration has been established as a crucial 
mechanism that satisﬁ es Knudson’s hypothesis that 
both alleles of a tumor suppressor gene (TSG) must be 
inactivated for carcinogenesis.  Promoter methylation 
and the associated event of histone deacetylation are 
epigenetic changes in chromatin structure that cause 
gene silencing without altering the DNA sequence 
[34,  35].  Methylation of TSGs,  including methyla-
tion of the RASSF1A gene,  has been observed in MM 
as well,  strongly suggesting that methylation of the 
promoter region of TSGs contributes to the neoplas-
tic transformation and progression of MM [36ﾝ39].  
Since the methylation proﬁ le varies with the histo-
logical subtype of the MMs,  the mechanism of neo-
plastic transformation may diﬀ er according to the 
histological subtype [37].  The methylation proﬁ le of 
MM is clearly diﬀ erent from those of adenocarcinoma 
of the lung,  and thus it can be used as a diagnostic 
tool [37].  Because the histological ﬁ ndings of these 2 
diseases are sometimes too similar to distinguish them,  
the methylation proﬁ le along with NF2 mutation status 
can be useful for performing diﬀ erential diagnosis.
　 Most of the studies of methylation in MM have thus 
far been conducted on specimens in the United States,  
where SV40 infection is suspected to be one of the 
causes.  Because the methylation proﬁ le of some genes 
diﬀ ers between SV40-infected and non-infected MMs,  
the methylation proﬁ le of MM in counties like Japan 
where there is no SV40 involvement may be totally 
diﬀ erent from that in the United States.  Our previous 
study indicates that methylation of the insulin-like 
growth factor-binding protein-3 (IGFBP-3) gene,  which 
is thought to control IGF function by suppressing the 
IGF-1 receptor,  has been shown to be more frequent 
in MM in Japan than in the United States.  This ﬁ nd-
ing suggests the presence of racial or regional diﬀ er-
ences in the genes that undergo methylation in MM 
[40].
　 Activation of telomerase. Telomerase activa-
tion,  which is thought to be one of the causes of 
immortalization,  is increased in malignant tumor cells.  













Fig. 1　　Schema showing the role of p16 and p14 in the cell 
cycle.  The loss of p16 and p14 function leads to alterations in cell 
cycle control,  resulting in cell proliferation and anti-apoptosis.  ＊G0 
arrest by p53 pathway mainly occurs when DNA is damaged.
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It is also known to be high in MM [41].  The expres-
sion of hTERT,  which is closely associated with 
telomerase activity,  has been found in 90ｵ of MM 
cases.  Since its expression is not observed in meso-
thelial cells in non-tumorous portions,  it may be 
capable of serving as a marker for the malignant 
transformation of mesothelial cells [41].
　 Cell proliferation. An increase in cell prolif-
eration is seen in MM as in other malignant tumors.  
Cell proliferation increases particularly as a result of 
the autocrine and paracrine function of growth fac-
tors: epidermal growth factor (EGF) [42],  hepato-
cyte growth factor (HGF) [43],  platelet-derived 
growth factor (PDGF) [44],  transforming growth fac-
tor ｹ[45],  IGF-1,  and IGF-II [46].  At the same 
time,  high levels of expression of the receptors for 
these growth factors such as EGFR,  c-MET,  and 
IGF-R1 have been found.  Moreover,  alterations of the 
Wnt signaling system,  which is involved in the prolif-
eration and generation of normal cells,  have recently 
been reported in MM [47].
　 Invasiveness and angiogenesis. MMs are 
highly locally invasive tumors but distant metastasis 
also sometimes occurs in advanced cases.  The matrix 
metalloproteinases (MMPs) MMP-2 and MMP-9,  in 
particular,  are known to be related to the invasion and 
metastasis of MM.  MMP-2 is also considered to be a 
negative prognostic factor [48].  It has also been sug-
gested that the microvessel density of tumors is a 
prognostic indicator [49],  and that the vascular endo-
thelial growth factor that contributes to angiogenesis 
is overexpressed [50].
　 Anti-apoptosis. The Bcl-2 family of proteins is 
known to be involved in apoptosis and strong expres-
sion of these protein is seen in many malignant tumors.  
Whereas the frequency of expression of Bcl-2 protein 
itself in MM is low,  strong expression of Bcl-XL (a 
member of the Bcl-2 family) and Bax,  which have 
potent anti-apoptotic potential,  has been found [51ﾝ
53].  Strong expression of the inhibitor of apoptosis 
protein (IAP) and survivin,  which are considered 
resistance factors for chemotherapy,  has also been 
observed [54].
　 Association with SV40. There is a hypothesis 
in western countries that infection with SV40,  a virus 
whose original hosts are monkeys,  is one of the caus-
ative factors of MM [55,  56].  In support of the 
hypothesis,  SV40 large T antigen DNA has been 
detected in approximately half of MM cases in the 
United States [57].  The reason why SV40 was 
detected in human tissue has been presumed to be that 
the polio vaccine produced between 1955 and 1963 
was contaminated with SV40 in the manufacturing 
process,  and that SV40 infected humans through 
inoculation with the contaminated vaccine.  There have 
been many arguments against this explanation,  and this 
topic continues to invite debate [58].  There is con-
cern that the vaccine that may have been contaminated 
was used in Japan from 1961 to 1963,  but the result 
of a study in Japan regarding the association between 
MM and SV40 was negative [59].  Inactivation of p53 
and Rb protein by SV40 large T antigen has been 
demonstrated as the mechanism of carcinogenesis by 
SV40 [60].  Moreover,  in human mesothelial cells 
that were infected with SV40 and immortalized,  an 
increase in hTERT activity was observed in the early 
stage,  and methylation and a decrease in the expres-
sion of the RASSF1A gene was observed in the late 
stage,  both of which are assumed to be related to 
SV40-associated MM [61,  62].  Malignant transfor-
mation of mesothelial cells by SV40 is thought to be 
promoted by its combination with the presence of 
asbestos [60].
　 Attempts at comprehensive analysis of 
expression. The diﬀ erential display and microar-
ray methods are useful assays for the comprehensive 
analysis of mRNA expression.  Attempts have been 
made to identify altered gene expression levels 
through the comprehensive analysis of mRNA expres-
sion in MM tissue and in non-tumorous tissue.  
Alterations in the level of variety gene expression,  
including the activation of apoptosis-associated genes 
and gene groups involved in glucose metabolism,  
mRNA transcription,  and cytoskeleton formation,  
have been occasionally reported [63,  64] but not uni-
versally identiﬁ ed.  Although some studies have also 
explored the possibility of identifying prognostic fac-
tors by expression proﬁ ling,  they have not reached the 
clinical application stage and require further investi-
gation [65,  66].
Concluding Remarks
　 The worldwide incidence of MM is considered to be 
increasing [1],  especially in Japan and non-western 
countries,  where asbestos continued to be heavily used 
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after its use had been discontinued in western coun-
ties.  Thus,  the urgent establishment of preventive,  
diagnostic and treatment strategies for MM is manda-
tory.  Also,  the roles of erionite and of genetic fac-
tors,  as shown by the outbreak in certain areas of 
Caddadochia,  Turkey,  can be crucial clues for under-
standing the pathogenesis of MM [67].  So far,  exten-
sive research has made some of the critical molecular 
alterations clear,  but the ﬁ ndings are still not ade-
quately reﬂ ected in clinical settings.  In terms of 
future tasks,  it will be necessary to apply what has 
been learned so far to clinical practice and to further 
elucidate the diseases using a molecular biological 
approach.
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